“R2M’s razor focused dedication to delivering quality small molecules that have the potential to be both first in class and best in class therapies make them an outstanding medicinal chemistry partner through
all stages of discovery and preclinical development, from hit validation through glp tox. studies. Julio Medina and the R2M team have worked closely with the biology, dmpk and cmc teams at Nura, at all times staying in lock step with the internal team and keeping up with the ever-changing needs and demands of early-stage programs. Julio is also very thoughtful and proactive with respect to IP strategy and is able to balance the competing needs of a small organization to deliver a robust patent portfolio. R2M has been an outstanding partner for Nura, serving as an extension of our team at multiple levels and joining forces with us to continue to deliver potentially transformative, disease-modifying therapies for patients. I strongly recommend R2M to research organizations pursuing small-molecule drug discovery projects.”